{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:25:57Z","timestamp":1649193957139},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,15]]},"DOI":"10.2146\/ajhp110567","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T17:18:25Z","timestamp":1338311905000},"page":"1044-1048","source":"Crossref","is-referenced-by-count":3,"title":["Combination exenatide\u2013sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus"],"prefix":"10.1093","volume":"69","author":[{"given":"Manav B.","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy, New Hanover Regional Medical Center, Wilmington, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey K.","family":"Elmore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa P.","family":"Edgerton","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, New Hanover Regional Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie M.","family":"Whalin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, New Hanover Regional Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041203525377900_b1-0691044","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and \u03b2-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"2019041203525377900_b2-0691044","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1210\/jc.2003-030049","article-title":"Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes","volume":"88","author":"Meier","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041203525377900_b3-0691044","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","article-title":"Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients","volume":"22","author":"Toft-Nielsen","year":"1999","journal-title":"Diabetes Care"},{"key":"2019041203525377900_b4-0691044","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2019041203525377900_b5-0691044","unstructured":"Amylin Pharmaceuticals Inc. Byetta (exenatide) package insert. San Diego, CA; 2009. http:\/\/pi.lilly.com\/us\/byetta-ppi.pdf (accessed 2010 Oct 20)."},{"key":"2019041203525377900_b6-0691044","unstructured":"Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta), October2007. www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124712.htm (accessed 2010 Oct 20)."},{"key":"2019041203525377900_b7-0691044","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"key":"2019041203525377900_b8-0691044","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"2019041203525377900_b9-0691044","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Ther"},{"key":"2019041203525377900_b10-0691044","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1742-1241.2006.01246.x","article-title":"Efficacy and tolerability of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes","volume":"61","author":"Scott","year":"2007","journal-title":"Int J Clin Pract"},{"key":"2019041203525377900_b11-0691044","volume-title":"Januvia (sitaglipitin) package insert","author":"Merck & Co., Inc","year":"2006"},{"key":"2019041203525377900_b12-0691044","unstructured":"Food and Drug Administration. Information for healthcare professionals: acute pancreatitis and sitagliptin, September252009. www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm183764.htm (accessed 2010 Oct 31)."},{"key":"2019041203525377900_b13-0691044","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2019041203525377900_b14-0691044","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"key":"2019041203525377900_b15-0691044","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/gut.44.1.81","article-title":"Glucagon-like peptide-1: a potent regulator of food intake in humans","volume":"44","author":"Gutzwiller","year":"1999","journal-title":"Gut"},{"key":"2019041203525377900_b16-0691044","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1464-5491.2000.00367.x","article-title":"Glucagon-like peptide (GLP)-1 and leptin concentrations in obesity patients with type 2 diabetes mellitus","volume":"17","author":"Mannucci","year":"2000","journal-title":"Diabet Med"},{"key":"2019041203525377900_b17-0691044","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"2019041203525377900_b18-0691044","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1194\/jlr.M300093-JLR200","article-title":"GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release","volume":"44","author":"Bulotta","year":"2003","journal-title":"J Lipid Res"},{"key":"2019041203525377900_b19-0691044","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1463-1326.2011.01362.x","article-title":"Effect of sitagliptin therapy on post-prandial lipoprotein levels in patients with type 2 diabetes","volume":"13","author":"Tremblay","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2019041203525377900_b20-0691044","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2337\/dc09-2062","article-title":"Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database","volume":"33","author":"Horton","year":"2010","journal-title":"Diabetes Care"},{"key":"2019041203525377900_b21-0691044","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"key":"2019041203525377900_b22-0691044","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0899-9007(01)00543-3","article-title":"Effect of a moderately energy-restricted diet on obese patients with fatty liver","volume":"17","author":"Okita","year":"2001","journal-title":"Nutrition"},{"key":"2019041203525377900_b23-0691044","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in anti-diabetic drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin Ther"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/12\/1044\/28361376\/ajhp1044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T23:53:28Z","timestamp":1555113208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/12\/1044\/5112769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,6,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110567","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,6,15]]},"published":{"date-parts":[[2012,6,15]]}}}